The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free...
Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...
Areas covered: This is a comprehensive review of the literature on the role of pembrolizumab in melanoma.
The primary purpose of this study is to compare the objective response rate (ORR) as determined by investigators, of Nivolumab...
BMS has announced positive results from a Phase II trial (CheckMate -069), evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen versus Yervoy...
BMS announced positive results of a Phase III trial (CheckMate -067) evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen or Opdivo monotherapy...
Bristol-Myers Squibb announced that the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with...
BMS announced that the FDA has accepted for filing and review a supplemental Biologics License Application (sBLA) for the combination...
The EMA has validated the application from BMS for Opdivo (nivolumab) + Yervoy (ipilimumab) to treat melanoma, the proposed new...
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.